Annals of Hematology

, Volume 86, Issue 4, pp 271–276 | Cite as

Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients

Original Article

Abstract

The anti-CD20 antibody rituximab improves the results of first-line therapy in aggressive non-Hodgkin’s lymphoma (NHL) of B cell lineage. The purpose of this retrospective study was to evaluate its efficacy and toxicity in combination with the doxorubicine, methylprednisolone, high-dose cytarabine, cisplatin (ASHAP) protocol, an established treatment regimen for relapsed or refractory aggressive NHL. After a median of four cycles, 9 of 20 patients treated achieved a complete remission and 6 a partial remission, resulting in a total response rate of 75%. Remissions were not only seen in patients with relapsed lymphomas but also in patients with primary refractory or transformed indolent lymphomas. The outcome in cases with an international prognostic index score ≥2 was poor. Five of 15 responders received consolidating high-dose therapy with autologous stem cell transplantation. All of them are in ongoing remission. The main toxicity was myelosuppression, with neutropenias or thrombocytopenias of World Health Organization (WHO) grades III or IV developing in more than 90% of the cycles. There was one therapy-related death due to neutropenic sepsis. Non-hematologic toxicity was generally mild. At the time of analysis, six patients have died. After a median observation time of 17.5 months, the 2-year overall survival rate is 62%. ASHAP plus rituximab is an active and well-tolerated salvage protocol for patients with relapsed or refractory aggressive NHL, which compares favourably with other immuno-chemotherapy regimens, especially in patients with primary refractory or transformed indolent lymphomas.

Keywords

ASHAP Anti-CD20 antibody rituximab Salvage chemotherapy Non-Hodgkin’s lymphoma Relapse 

Notes

Acknowledgement

This paper is dedicated to Professor Günter Brittinger on the occasion of his 75th birthday.

References

  1. 1.
    Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545PubMedCrossRefGoogle Scholar
  2. 2.
    Philip T, Armitage JO, Spitzer G et al (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 316:1493–1498PubMedCrossRefGoogle Scholar
  3. 3.
    Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F (1991) Treatment of relapsed non-Hodgkin’s lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9:423–431PubMedGoogle Scholar
  4. 4.
    Velasquez WS, Cabanillas F, Salvador P et al (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117–122PubMedGoogle Scholar
  5. 5.
    Nückel H, Dürig J, Dührsen U (2003) Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin’s lymphomas. Ann Hematol 82:481–486PubMedCrossRefGoogle Scholar
  6. 6.
    Hänel M, Kröger N, Hoffknecht MM et al (2000) ASHAP—an effective salvage therapy for recurrent and refractory malignant lymphomas. Ann Hematol 79:304–311PubMedCrossRefGoogle Scholar
  7. 7.
    Velasquez W, Dunphy F, Petruska PJ, Adkins D, Broun GO Jr, Spitzer G (1995) ASHAP with or without ABMT for high risk non-Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol 14:387 (Abstr 1205)Google Scholar
  8. 8.
    Velasquez W, Dunphy F, Santillana S, Adkins D, Browers C, Broun GO Jr, Petruska PJ, Spitzer G (1993) ASHAP, an effective treatment for relapsing and refractory Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL). Blood 82(Suppl 1):138a (Abstr 538)Google Scholar
  9. 9.
    Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMedCrossRefGoogle Scholar
  10. 10.
    Coiffier B, Haioun C, Ketterer N et al (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927–1932PubMedGoogle Scholar
  11. 11.
    Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821–830PubMedCrossRefGoogle Scholar
  12. 12.
    Rothe A, Schulz H, Elter T, Engert A, Reiser M (2004) Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin’s lymphoma. Haematologica 89:875–876PubMedGoogle Scholar
  13. 13.
    Kewalramani T, Zelenetz AD, Nimer SD et al (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684–3688PubMedCrossRefGoogle Scholar
  14. 14.
    Venugopal P, Gretory S, Showel J et al (2004) Rituximab (Rituxan) combined with ESHAP chemotherapy is highly active in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts) 104:4636, (Abstract)Google Scholar
  15. 15.
    Hicks L, Buckstein R, Piliotis E et al (2004) Rituximab + ESHAP as salvage chemotherapy for relapsed/refractory aggressive non-Hodgkins lymphoma: a phase II trial. Blood (ASH Annual Meeting Abstracts) 104:5230, (Abstract)Google Scholar
  16. 16.
    Mey U, Strehl J, Orlopp KS et al (2004) A phase II trial of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts) 104:4618, (Abstract)Google Scholar
  17. 17.
    Rupolo M, Spina M, Michieli M et al (2004) R-DHAOX as salvage regimen in patients (pts) with relapsed/resistant non-Hodgkins lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 104:1323, (Abstract)Google Scholar
  18. 18.
    Wenger C, Stern M, Herrmann R, Rochlitz C, Pless M (2005) Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin’s lymphoma? Leuk Lymphoma 46:71–75PubMedCrossRefGoogle Scholar
  19. 19.
    Gnaoui T, Dupuis J, Joly B et al (2004) Rituximab, gemcitabine and oxaliplatin (R-GEMOX): a promising regimen for refractory/relapsed B-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 104:2483, (Abstract)Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Hematology, Medical FacultyUniversity of Duisburg-EssenEssenGermany

Personalised recommendations